Title
Variation in HIV-1 Nef function within and among viral subtypes reveals genetically separable antagonism of SERINC3 and SERINC5.

Permalink
https://escholarship.org/uc/item/3gr4z6wn

Journal
PLoS pathogens, 16(9)

ISSN
1553-7366

Authors
Jin, Steven W
Mwimanzi, Francis M
Mann, Jaclyn K
et al.

Publication Date
2020-09-14

DOI
10.1371/journal.ppat.1008813

Peer reviewed
Variation in HIV-1 Nef function within and among viral subtypes reveals genetically separable antagonism of SERINC3 and SERINC5

Steven W. Jin, Francis M. Mwimanzi, Jaclyn K. Mann, Mwebesa Bosco Bwana, Guinevere Q. Lee, Chanson J. Brumme, Peter W. Hunt, Jeff N. Martin, David R. Bangsberg, Thumbi Ndungu, Zabrina L. Brumme, Mark A. Brockman

Abstract

HIV Nef counteracts cellular host restriction factors SERINC3 and SERINC5, but our understanding of how naturally occurring global Nef sequence diversity impacts these activities is limited. Here, we quantify SERINC3 and SERINC5 internalization function for 339 Nef clones, representing the major pandemic HIV-1 group M subtypes A, B, C and D. We describe distinct subtype-associated hierarchies for Nef-mediated internalization of SERINC5, for which subtype B clones display the highest activities on average, and of SERINC3, for which subtype B clones display the lowest activities on average. We further identify Nef polymorphisms that modulate its ability to counteract SERINC proteins, including substitutions in the N-terminal domain that selectively impair SERINC3 internalization. Our findings demonstrate that the SERINC antagonism activities of HIV Nef differ markedly among major viral subtypes and between individual isolates within a subtype, suggesting that variation in these functions may contribute to global differences in viral pathogenesis.

Author summary

Cellular restriction factors dampen viral replication and reduce pathogenesis. In response, HIV has evolved a variety of mechanisms to counteract restriction factors, including the
ability of its Nef protein to internalize Serine incorporator (SERINC) proteins 3 and 5 from the infected cell surface, thereby enhancing infectivity of viral particles. Nef displays substantial sequence diversity, but how this impacts SERINC antagonism remains unclear. To examine this, we used cell culture models to measure SERINC internalization function for 339 participant-derived Nef clones, representing four globally relevant HIV-1 group M subtypes. We observed significant variability in Nef function among circulating viral strains and subtypes. We also identified naturally occurring Nef mutations that modulate its ability to counteract SERINC proteins, including some that selectively impair SERINC3 internalization. These findings uncover viral features that may contribute to global differences in HIV pathogenesis and provide new insight into the interactions between Nef and SERINC restriction factors that can inform future mechanistic studies.

Introduction

Cellular restriction factors impede HIV replication [1–5]. In response, HIV has evolved strategies to counteract these intrinsic host antiviral molecules [6]. Among the most recent restriction factors to be identified are members of the Serine incorporator (SERINC) family of multi-pass transmembrane proteins, namely SERINC3 and SERINC5, which are antagonized by the HIV accessory protein Nef [7–9]. Nef is a 27–35 kD cytosolic protein that plays a crucial role in viral pathogenesis [10–12]. Through its various interactions with cellular protein trafficking machinery, Nef internalizes CD4 [13], HLA class I [14–16], SERINC3 and SERINC5 [7, 8] as well as other proteins from the surface of infected cells, thereby enhancing viral replication and evading host immune responses. The presence of SERINC proteins in viral particles interferes with the generation of a fusion pore following binding to a target cell [17], thus impeding viral entry. SERINC5 appears to be more potent at blocking HIV entry compared to SERINC3 [8]. As a result, most reports focus on Nef’s ability to antagonize SERINC5, and its impact on SERINC3 remains relatively understudied. While the mechanism of SERINC’s antiviral activity has not been fully clarified, a recent study found that SERINC5 disrupts viral Envelope (Env) clusters on the virion surface through an indirect process [18]; however, other studies suggest that a direct interaction between Env and SERINC5 may result in conformational changes to Env that impair its function [19, 20]. Regardless of the precise mechanism(s) of action, by removing SERINC proteins from the infected cell surface, Nef reduces their incorporation into virions and counteracts their antiviral function [7, 8].

The HIV-1 group M (Main) pandemic strains comprise nine genetically diverse subtypes (A–D, F–H, J and K) and nearly 100 circulating recombinant forms [21]. Viral subtype is a key determinant of clinical progression [22, 23], as demonstrated by the observation that subtypes A and C are associated with reduced pathogenesis compared to subtype D in regions where these viruses co-circulate [24–26]. While strain-specific differences in simian immunodeficiency virus (SIV) Nef-mediated SERINC5 antagonism correlate with the prevalence of lentiviral infections in wild primates [27], the impact of global HIV Nef sequence diversity on its SERINC antagonism activities remains incompletely characterized. Consistent with the hypothesis that naturally occurring variation in Nef function may play an analogous role in HIV infection, initial studies reported that Nef clones from infected individuals differed in their ability to antagonize SERINC proteins [7, 27]. Prior work from our group also indicates that naturally occurring variation in Nef sequences yields substantial diversity in several of Nef’s best-characterized functions, including CD4 and HLA class I internalization [28–32]. Moreover, we recently reported that Nef clones isolated from HIV elite controllers, who
suppress plasma viremia in the absence of antiretroviral therapy, often display reduced ability to internalize SERINC5 [33], suggesting that variability in Nef-mediated SERINC antagonism contributes to clinical outcome in at least some individuals.

To date, no large-scale studies have characterized the extent to which Nef’s ability to antagonize SERINC proteins varies among global HIV subtypes. Here, we examined a diverse panel of 339 Nef clones isolated from individuals infected with subtypes A, B, C, or D for their ability to internalize SERINC3 and SERINC5. We observed that SERINC3 and SERINC5 antagonism activity varies markedly among circulating Nef isolates and between viral subtypes. Notably, while subtype B Nef clones displayed superior abilities to internalize SERINC5, they were frequently impaired in their ability to internalize SERINC3. We further identified natural polymorphisms in Nef that were associated with variation in SERINC3 and/or SERINC5 internalization function, including substitutions at Nef residues 8 and 11 that impaired its ability to counteract SERINC3, but not SERINC5. Our results indicate that variation in Nef-mediated SERINC antagonism may contribute to differences in pathogenesis among HIV subtypes.

Results
SERINC internalization function varies markedly among HIV Nef isolates

We assembled a diverse panel of 339 HIV Nef clones consisting of unique isolates obtained from individuals residing in Canada, Uganda or South Africa who were infected with HIV subtype A, B, C, or D, as reported previously [30]. These nef sequences clustered into distinctive subtypes (Fig 1A) and did not include viral recombinants that could confound analysis. Each Nef clone was characterized for its ability to internalize SERINC3 and SERINC5 from the cell surface using a transient expression assay (described in the Methods). Briefly, CEM CD4 T cells were co-transfected with plasmids expressing a Nef clone and one of the SERINC proteins, which was modified to encode an internal HA tag (iHA). SERINC expression was quantified by detecting the HA tag on the surface of non-permeabilized cells using flow cytometry. Consistent with prior studies [8, 33], a Nef clone derived from the subtype B SF2 strain efficiently internalized SERINC5 but not SERINC3, while a Nef clone derived from the subtype B NL4.3 strain internalized both proteins (S1 Fig). As such, SERINC internalization results for each Nef clone were normalized to those of NL4.3 Nef, such that activities greater than or less than NL4.3 Nef are indicated by values above or below 100%, respectively.

The 339 Nef clones differed widely in their ability to internalize the SERINC proteins: the median SERINC3 internalization function of all clones relative to the NL4.3 Nef control was 78 [interquartile range (IQR) 48–97]%., while the median SERINC5 internalization function was 94 [IQR 77–102]% (Mann-Whitney; p < 0.0001) (Fig 1B). The observation that SERINC5 internalization was overall more conserved than SERINC3 internalization suggests that it may be less crucial for Nef to maintain the latter activity in vivo, in at least some cases. This result is also consistent with prior in vitro studies demonstrating that SERINC3 displays lower antiviral activity compared to SERINC5 [8]. Stratification of the data by viral subtype revealed significant differences in Nef-mediated SERINC3 and SERINC5 internalization function as well as distinct functional hierarchies for the two proteins (Fig 1C and 1D). Specifically, subtype B Nef clones displayed the highest function for SERINC5 internalization (median 102 [IQR 96–110]%.) followed closely by subtype D clones (median 98 [IQR 74–104]%.) (Mann-Whitney; p = 0.0005), while clones derived from subtype C (median 89 [IQR 74–99]%.) and subtype A (median 83 [IQR 67–95]%.) displayed lower abilities to internalize this protein (pairwise Mann-Whitney; all p < 0.005 vs. B and D) (Fig 1D). In contrast, SERINC3 internalization function was comparable among Nef clones derived from subtypes D (median 88 [IQR 64–97]%), A (median 83 [IQR 50–100]%), and C (median 82 [IQR 50–96]%) (pairwise Mann-Whitney;
all $p>0.05$), whereas subtype B clones displayed lower ability to internalize this protein (median 55 [IQR 28–92]% (pairwise Mann-Whitney; all $p<0.05$).

Consistent with the relatively high functional variability observed among Nef clones, we found only a weak association between SERINC3 and SERINC5 internalization functions when all clones were considered (Spearman $R = 0.21$; $p<0.0001$) (S2 Fig); however, this improved notably when subtype B clones were excluded ($R = 0.47$; $p<0.0001$). Furthermore, stratification of these data according to viral subtype resulted in moderate to strong correlations between SERINC3 and SERINC5 internalization function for Nef clones from subtypes A, C or D ($R = 0.37$ to 0.62; all $p<0.001$), but there was no similar association for subtype B.
clones (R = 0.04; p = 0.74). Next, we assessed possible associations between SERINC antagonism and Nef’s other major internalization functions, namely downregulation of CD4 and HLA class I (HLA-I), which we reported previously for this panel of Nef clones [30] (S3 Fig). Consistent with our study of Nef clones derived from HIV controllers [33], a strong correlation was observed between SERINC5 and CD4 internalization functions (Spearman R = 0.53; p < 0.0001), while a more moderate association was found between SERINC5 and HLA class I internalization (R = 0.32; p < 0.0001). Overall, SERINC3 internalization function correlated modestly with CD4 downregulation (R = 0.20; p < 0.0001), but this association was strengthened when subtype B clones were excluded (R = 0.41; p < 0.001). A modest inverse association was found between SERINC3 and HLA-I internalization functions (R = -0.19; p < 0.001), but this was not apparent after removal of subtype B clones and thus its relevance is unclear.

Finally, to assess whether variable Nef expression or stability could be responsible for the observed differences in SERINC antagonism function, we quantified steady-state protein levels for 61 randomly selected Nef clones (representing all subtypes) by Western blot. We observed no association between protein detection and function for these clones.

Together, these results demonstrate substantial variability in SERINC3 and SERINC5 internalization function among natural HIV Nef isolates and also identify a more pronounced impairment in SERINC3 internalization among subtype B clones. Stronger associations between SERINC and CD4 downregulation are consistent with other data suggesting a shared cellular mechanism of Nef-mediated internalization for these proteins [7, 9].

**Nef-mediated antagonism of SERINC3 and SERINC5 enhances HIV infectivity**

To complement the results of SERINC internalization assays, we next investigated the impact of different nef alleles on viral infectivity. Such assays have typically produced viruses using HEK293T cells, however, these cells express high levels of SERINC3 relative to CD4 T-cell lines [8], which limits our ability to modulate SERINC3 expression [34]. To overcome this, we disrupted SERINC3 in 293T cells using CRISPR/Cas9 as described in Methods and validated the SERINC3 knockout (KO) cell line by confirming the infectivity of wild type and Nef-deleted NL4.3 strains produced using these cells (Fig 2A). While Nef enhanced viral infectivity ~three-fold in parental 293T cells [7, 35], the infectivity of wild type and Nef-deleted NL4.3 viruses did not differ when they were produced using SERINC3 KO cells, consistent with the inactivation of this key restriction factor. Furthermore, rescue of SERINC expression in these cells by co-transfection of pSERINC3(iHA) or pSERINC5(iHA) reduced the infectivity of Nef-deleted virus by 8-fold or 55-fold, respectively, confirming that SERINC5 is a more potent restriction factor in this model.

Using the SERINC3 KO cell line, we generated 82 NL4.3-derived viruses encoding selected nef alleles in the presence or absence of each SERINC protein. As expected, the infectivity of viruses produced in the presence of SERINC3 alone correlated strongly with our measures of Nef-mediated internalization of this protein (Spearman R = 0.62, p < 0.0001) (Fig 2B), but less so with our measures of SERINC5 internalization (Spearman R = 0.31, p = 0.004). Conversely, the infectivity of viruses produced in the presence of SERINC5 alone correlated strongly with our measures of Nef-mediated internalization of this protein (Spearman R = 0.63, p < 0.0001), but less so with our measures of SERINC3 internalization (Spearman R = 0.32, p = 0.003) (Fig 2C). The specificity of these correlations supports the notion that Nef uses somewhat distinct mechanisms to internalize SERINC3 and SERINC5.

Notably, when viruses were produced in the presence of both SERINC proteins, infectivity correlated with Nef-mediated SERINC5 internalization (Spearman R = 0.50, p < 0.0001), but
Natural variation in Nef-mediated SERINC antagonism
not with SERINC3 internalization (Spearman R = 0.15, p = 0.13) (Fig 2D). This result indicates that SERINC5 plays a dominant role in modulating HIV infectivity, and is consistent with reports identifying it as the more potent restriction factor [7, 8]. Overall, our data demonstrate that Nef-mediated SERINC internalization function is closely linked with its overall impact on viral infectivity in the presence of SERINC proteins, though other Nef functions may also contribute to this outcome [36].

Nef polymorphisms associate with SERINC antagonism activity

Given the marked variation in SERINC antagonism activity among Nef clones and the substantial differences in the ability of subtype B clones to counteract SERINC5 versus SERINC3, we analyzed our sequence/function dataset in a subtype-specific manner to identify viral polymorphisms associated with each Nef function (see Methods). We identified 73 nef polymorphisms, located at 48 Nef residues, associated with SERINC5 internalization function (Mann-Whitney; all p<0.05) (Table 1 and S1 Table). These residues were distributed relatively evenly across Nef’s major domains (i.e. N-terminal anchor, globular core, flexible loop and C-terminal tail) [37, 38] (Fig 3A and 3D), suggesting that natural variation in multiple regions of the protein contribute to this activity. The strongest of these associations occurred at Nef residue 94 in subtype B, where the presence of consensus Lysine correlated with better SERINC5 internalization (Mann-Whitney; p<0.0002). Notably, Nef K94E was associated with reduced SERINC5 internalization function in an independent panel of subtype B Nef clones isolated from HIV elite controllers and progressors published by our group [33]. In that report, we confirmed that K94E impaired Nef’s SERINC5 internalization function and reduced its ability to enhance viral infectivity in the presence of SERINC5. New associations with Nef function that were identified through this analysis, including those at residues 60 and 180 in subtype A, 61 and 197 in subtype B, 88 and 98 in subtype C, and 57 and 114 in subtype D (Mann-Whitney; all p<0.01), warrant further investigation.

We also identified 108 nef polymorphisms, located at 45 Nef residues, associated with SERINC3 internalization function (Mann-Whitney; all p<0.05) (Table 2 and S2 Table). Of note, these were modestly enriched (24, or 53%) at sites located in the N-terminal anchor (codons 1–57) (Fig 3B and 3E), suggesting that Nef’s ability to internalize SERINC3 may be particularly sensitive to changes in this region. Remarkably, in all subtypes tested, the strongest correlations were located at Nef residues 8 and/or 11, where the presence of consensus Serine or Valine, respectively, correlated with better SERINC3 internalization function. These
associations were most statistically significant for clones derived from subtypes A and B (all \( p \lt 0.00001 \)).

In total, 71 Nef residues (of 206, 34%) were associated with either SERINC3 or SERINC5 internalization function. Twenty-two Nef residues were associated with both functions (Fig 3C and 3F; S3 Table), suggesting shared structural motifs or interacting domains that contribute to both activities, while 49 were associated with only one function, suggesting regions of the protein that play a unique role in Nef’s ability to counteract SERINC3 or SERINC5. Notably, Nef residue 94 was not associated with SERINC3 internalization function, and neither residue 8 nor 11 were associated with SERINC5 internalization function, indicating that these two activities are genetically separable.

## Polymorphisms at Nef codons 8 and 11 selectively impair SERINC3 antagonism activity

Our codon-function analyses indicated that polymorphisms at Nef residues 8 and 11 should attenuate its ability to internalize SERINC3, but not SERINC5. To confirm this observation and to assess the impact of these polymorphisms on two of Nef’s other major functions, namely CD4 and HLA class I internalization, we introduced S8R and I11G substitutions into NL4.3 Nef. These alternative amino acids at residues 8 and 11 are common in our dataset and are predicted to selectively impair SERINC3 internalization. Both mutants displayed normal abilities to internalize CD4, HLA class I and SERINC5, but SERINC3 internalization was severely reduced (50% activity for S8R; 0% activity for I11G) (Fig 4A). To confirm that this loss of function was not particular to HIV subtype B, we introduced S8R or I/11G substitutions into selected subtype A, C and D Nef clones that displayed normal abilities to internalize

### Table 1. Selected Nef polymorphisms associated with SERINC5 internalization function.

| Subtype | Residue | Domain * | Amino Acid | Median Function (With) | Median Function (Without) | N (With) | N (Without) | p-value |
|---------|---------|----------|------------|------------------------|---------------------------|----------|-------------|---------|
| A       | 60      | Globular core | E         | 46                     | 85                        | 4        | 88          | 0.008   |
| A       | 60      | Globular core | A         | 85                     | 51                        | 87       | 5           | 0.03    |
| A       | 180     | C-terminal  | T         | 76                     | 90                        | 54       | 38          | 0.005   |
| A       | 180     | C-terminal  | V         | 90                     | 76                        | 38       | 54          | 0.005   |
| B       | 61      | Globular core | Q         | 109                    | 90                        | 86       | 5           | 0.009   |
| B       | 61      | Globular core | Y         | 82                     | 108                       | 3        | 88          | 0.01    |
| B       | 94      | Globular core | K         | 110                    | 96                        | 77       | 14          | 0.0001  |
| B       | 94      | Globular core | E         | 82                     | 109                       | 7        | 84          | 0.006   |
| B       | 197     | C-terminal  | E         | 108                    | 76                        | 88       | 3           | 0.006   |
| C       | 3       | N-terminal anchor | G       | 94                     | 75                        | 48       | 23          | 0.009   |
| C       | 3       | N-terminal anchor | N       | 62                     | 91                        | 6        | 65          | 0.02    |
| C       | 32      | N-terminal anchor | A       | 87                     | 101                       | 64       | 7           | 0.005   |
| C       | 32      | N-terminal anchor | T       | 101                    | 88                        | 3        | 68          | 0.02    |
| C       | 88      | Globular core | G         | 70                     | 91                        | 15       | 56          | 0.008   |
| C       | 88      | Globular core | S         | 91                     | 70                        | 56       | 15          | 0.008   |
| C       | 98      | Globular core | D         | 82                     | 95                        | 34       | 37          | 0.006   |
| C       | 98      | Globular core | E         | 95                     | 82                        | 37       | 34          | 0.006   |
| D       | 57      | N-terminal anchor | W       | 101                    | 51                        | 81       | 4           | 0.008   |
| D       | 114     | Globular core | V         | 101                    | 64                        | 73       | 12          | 0.003   |
| D       | 114     | Globular core | I         | 76                     | 101                       | 10       | 75          | 0.02    |

* Domain nomenclature based on [37, 38].

https://doi.org/10.1371/journal.ppat.1008813.t001
SERINC3. SERINC3 internalization was reduced in all cases, though to varying extents (Fig 4B). Since many circulating subtype B Nef clones encode both R8 and G11 polymorphisms and display impaired SERINC3 internalization, we attempted to rescue this activity in a subtype B Nef clone with relatively poor function by reverting these amino acids. While individual reversions of R8S or G11V showed no effect in this clone, the double-reversion (R8S and G11V) restored SERINC3 internalization function from 45 to 79%, relative to NL4.3 (Fig 4C). These results confirm that polymorphisms at Nef residues 8 and 11 can impair its ability to
internalize SERINC3. Furthermore, this impairment appears to be selective, since no major effects were observed on Nef’s abilities to internalize CD4, HLA class I or SERINC5.

To further examine global Nef sequence diversity at residues 8 and 11, we calculated amino acid frequencies at these sites based on 3775 publicly available Nef sequences from subtypes A, B, C or D (www.hiv.lanl.gov/; query restricted to one Nef sequence per individual). Consistent with our panel of 339 Nef clones, Serine and Valine were highly conserved at positions 8 and 11, respectively, in subtype A, C and D sequences, but these residues were highly polymorphic in subtype B (Fig 4D). This is consistent with our observation that circulating subtype A, C and D strains are more likely to retain SERINC3 antagonism activity compared to subtype B strains.

Finally, to investigate the effect of polymorphisms at Nef residues 8 or 11 on viral infectivity, we introduced S8R or I11G mutations into NL4.3, generated viruses in the presence of SERINC3, and measured their infectivity, as described previously. Overall, viruses encoding S8R or I11G were 3.3-fold and 4.4-fold less infectious compared to NL4.3, respectively (Fig 4E). These results indicate that both mutations impaired Nef’s ability to counteract SERINC3 to a degree that was similar to that of a Nef-deleted virus (which displayed a ~4-fold reduction in this assay).

Table 2. Selected Nef polymorphisms associated with SERINC3 internalization function.

| Subtype | Residue | Domain*         | Amino Acid | Median Function (With) | Median Function (Without) | N (With) | N (Without) | p-value |
|---------|---------|-----------------|------------|------------------------|---------------------------|----------|-------------|---------|
| A       | 8       | N-terminal anchor | S          | 96                     | 40                        | 73       | 17          | 4E-06   |
| A       | 8       | N-terminal anchor | R          | 42                     | 93                        | 9        | 81          | 0.002   |
| A       | 10      | N-terminal anchor | I          | 97                     | 48                        | 65       | 23          | 9E-06   |
| A       | 10      | N-terminal anchor | K          | 36                     | 94                        | 10       | 78          | 0.0001  |
| A       | 11      | N-terminal anchor | V          | 96                     | 37                        | 72       | 16          | 1.2E-06 |
| A       | 11      | N-terminal anchor | A          | 31                     | 92                        | 6        | 82          | 0.0003  |
| A       | 14      | N-terminal anchor | P          | 92                     | 41                        | 82       | 10          | 0.002   |
| B       | 8       | N-terminal anchor | S          | 92                     | 51                        | 37       | 46          | 6E-06   |
| B       | 8       | N-terminal anchor | R          | 51                     | 76                        | 28       | 55          | 0.004   |
| B       | 11      | N-terminal anchor | V          | 94                     | 43                        | 30       | 47          | 9E-07   |
| B       | 11      | N-terminal anchor | S          | 36                     | 69                        | 7        | 70          | 0.01    |
| B       | 14      | N-terminal anchor | P          | 71                     | 39                        | 57       | 34          | 0.0009  |
| B       | 14      | N-terminal anchor | A          | 31                     | 56                        | 8        | 83          | 0.04    |
| C       | 8       | N-terminal anchor | R          | 47                     | 88                        | 5        | 63          | 0.02    |
| C       | 11      | N-terminal anchor | V          | 91                     | 48                        | 52       | 14          | 0.001   |
| C       | 11      | N-terminal anchor | A          | 50                     | 88                        | 4        | 62          | 0.04    |
| C       | 40      | N-terminal anchor | Y          | 93                     | 67                        | 31       | 40          | 0.006   |
| C       | 49      | N-terminal anchor | A          | 66                     | 94                        | 40       | 31          | 0.005   |
| C       | 49      | N-terminal anchor | P          | 96                     | 76                        | 11       | 60          | 0.01    |
| D       | 8       | N-terminal anchor | S          | 94                     | 67                        | 69       | 13          | 0.0002  |
| D       | 8       | N-terminal anchor | R          | 70                     | 93                        | 10       | 72          | 0.007   |
| D       | 14      | N-terminal anchor | P          | 90                     | 38                        | 80       | 5           | 0.003   |
| D       | 14      | N-terminal anchor | S          | 37                     | 89                        | 4        | 81          | 0.007   |
| D       | 40      | N-terminal anchor | Y          | 103                    | 86                        | 4        | 81          | 0.007   |
| D       | 64      | Globular core     | E          | 83                     | 95                        | 64       | 21          | 0.006   |
| D       | 100     | Globular core     | I          | 104                    | 86                        | 4        | 81          | 0.003   |

a Domain nomenclature based on (37, 38).

https://doi.org/10.1371/journal.ppat.1008813.t002
Fig 4. Polymorphisms at Nef residues 8 and 11 selectively impair SERINC3 internalization function. (A) The relative abilities of NL4.3 Nef mutants S8R and I11G to internalize CD4, HLA class I, SERINC5 and SERINC3 are shown. Results are normalized to wild type NL4.3 Nef (100%). Internalization function was assessed by flow cytometry following transfection of CEM T cells as described in the Methods. (B) The relative abilities of representative Nef clones from subtype A (red), subtype C (green) and subtype D (blue) and their respective mutants at positions 8 and 11 to internalize SERINC3 are displayed. (C) The relative abilities of a representative participant-derived subtype B Nef clone and its respective reversion mutations at positions 8 and 11 to internalize SERINC3 are shown. (D) Amino acid frequencies at Nef codons 8 and 11, based on 3775 Nef sequences representing HIV-1 subtypes A, B, C and D obtained from the Los Alamos National Labs HIV sequence database, are shown. (E) The relative infectivities of NL4.3-derived viruses encoding S8R or I11G mutations produced in the presence of SERINC3 are shown. Statistical analyses were conducted using the unpaired Students T test. Significant differences compared to Nef controls are indicated by asterisks (* = p<0.05; ** = p<0.01; *** = p<0.001).

https://doi.org/10.1371/journal.ppat.1008813.g004
Nef residues 8 and 11 contribute to co-localization with SERINC3

Since polymorphisms at Nef residues 8 and 11 negatively impacted SERINC3 internalization but had negligible effects on CD4, HLA class I or SERINC5 internalization, we hypothesized that these residues are crucial for Nef to interact with SERINC3. To explore this possibility, we used the proximity ligase assay (PLA) to investigate the intracellular co-localization of Nef with SERINC3(iHA) and SERINC5(iHA), as described in Methods. This method generates a fluorescent signal if two proteins of interest are located within ~40 nm of each other inside the cell [39], thus allowing potential interactions to be measured semi-quantitatively as the median fluorescence intensity (MFI) of cells by flow cytometry. Using PLA, we observed a ~7-fold induction of fluorescent signal in cells expressing wild type Nef and SERINC3 (Fig 5A) or SERINC5 (Fig 5D) compared to background signal generated by control cells lacking Nef. In contrast, the MFI of cells expressing Nef S8R or I11G mutants and SERINC3 was markedly lower (62% or 55% relative to wild type Nef, respectively) (Fig 5B), suggesting that the impaired internalization function of these mutants is due at least in part to a reduced ability to co-localize with SERINC3. Notably, the same mutants displayed PLA signals similar to wild type Nef in the presence of SERINC5 (both >95%) (Fig 5D and 5E), which also consistent with their ability to internalize SERINC5 as efficiently as wild type Nef. Finally, similar detection of steady-state Nef and SERINC(iHA) by Western blot (Fig 5C and 5F) indicated that variation in PLA signal was unlikely to be due to differences in protein expression or antibody recognition.

Discussion

HIV group M subtypes A, B, C and D collectively account for ~75% of the global pandemic. Nef is a crucial determinant of viral pathogenesis, and also ranks among the most variable regions in the HIV genome [40, 41], suggesting that differences in Nef function may contribute to clinical outcome. Our analysis of 339 diverse Nef clones from these four major HIV subtypes demonstrates that subtype A and C clones displayed lower ability to internalize SERINC5 compared to those from subtypes B and D. This raises the intriguing possibility that an attenuated capacity to counteract SERINC5 may contribute to decreased pathogenesis in the context of subtype A or C infection, which has been seen in regions where these strains co-circulate with subtype D [24]. Also of note, subtype D Nef clones were most efficient at countering both SERINC3 and SERINC5, suggesting that this feature could also be linked to the increased pathogenesis of this subtype. Indeed, over half (43 of 85, 51%) of subtype D clones displayed an ability to internalize both restriction factors at levels above the cohort-wide median for each function, while only 26% of subtype A, 23% of subtype B, and 35% of subtype C Nef clones met this threshold (S2 Fig).

In contrast to a prior study of SIV Nef isolates that reported a correlation between SERINC5 antagonism activity and prevalence of SIV strains in wild primates [27], our results indicate that Nef’s ability to counteract SERINC5 (or SERINC3) does not obviously correlate with global HIV subtype prevalence: indeed, subtype C accounts for nearly 50% of all HIV infections worldwide [21], yet subtype C Nef clones displayed lower median SERINC5 internalization function compared to those from subtypes B and D in our assays. This apparent discrepancy between SIV and HIV may be due to a greater contribution of population-level factors other than viral fitness to the spread of HIV subtypes globally, including founder events [42], human social changes and complex transport networks [43, 44].

Our finding that Nef-mediated antagonism of SERINC3 displayed a distinct functional hierarchy among viral subtypes compared to that of SERINC5 indicates that these two closely related Nef activities are in fact functionally separable and further suggests that in vivo
selection pressures to maintain these two Nef activities might differ. Indeed, the majority of subtype B Nef clones internalized SERINC5 efficiently but were impaired in their ability to counteract SERINC3, whereas SERINC3 antagonism activity was maintained in most Nef clones derived from subtypes A, C and D. We also discovered that these differences in SERINC3 antagonism could largely be attributed to residues in Nef’s N-terminal anchor region, which allows the protein to interact with the inner leaflet of the plasma membrane as well as a variety of cellular kinases that are critical to its function [45]. In particular, we demonstrated that polymorphisms at residues 8 and 11 reduced Nef’s ability to co-localize with SERINC3 (but not SERINC5) based on PLA staining. These results suggest that Nef engages SERINC3 and SERINC5 at different locations within the cell, an intriguing possibility that will require more study. Notably, we observed that subtype B strains displayed the poorest SERINC3
antagonism activity, on average, of all subtypes tested, which is consistent with the presence of R8 and G11 as consensus amino acids in these isolates. Though the implications of this for viral transmission and spread remain unknown, we note that HIV subtype B dominates the Western world as a result of founder effects [46], but it has not survived in central Africa where it originated [47], possibly because it was outcompeted by the diverse HIV strains circulating there.

While we have not explored the mechanisms that underlie differential Nef function among viral subtypes, it is conceivable that host evolutionary pressures have contributed at least in part. With respect to this, we acknowledge that the subtype A, C and D clones used in our study were collected primarily from female participants in East and Southern Africa who were likely infected via heterosexual sex, while subtype B isolates were collected primarily from Canadian participants, mostly men who have sex with men. Our study was not designed to evaluate the potential impact of sex and additional research on this topic is needed. SERINC expression levels can also vary among individuals [48], which may influence the effectiveness of Nef-mediated SERINC antagonism and also contribute to population-level selection of Nef alleles. Additional studies are warranted to examine the contribution of host genetics and other aspects of the immune response on the antiviral activity of SERINC restriction factors.

The importance of Nef-mediated SERINC antagonism for HIV pathogenesis remains to be elucidated. Our understanding of SERINC restriction mechanisms, and Nef’s role as a mediator of viral infectivity (apart from its ability to counteract SERINC), continues to evolve [49, 50]. While we observed strong correlations between Nef’s ability to internalize SERINC proteins and its ability to enhance viral infectivity, we did not directly measure SERINC incorporation into virions. Indeed, while most studies have observed an inverse association between the amount of SERINC incorporated into virions and their infectivity [7, 8, 17], supporting Nef-mediated sequestering of SERINC as a major strategy to counteract its antiviral activity, some reports suggest that Nef can antagonize SERINC without altering its levels in virion particles [51, 52]; thus, other known or unknown [50] Nef activities may contribute to our observations. In addition, Nef’s ability to counteract SERINC3 or SERINC5 is likely to depend in part on the relative expression levels of each protein [51, 53]. In our studies, we titrated SERINC proteins to enhance detection of Nef’s effects, but this may not fully recapitulate natural variation in SERINC expression seen among diverse human populations. Nef expression (as detected by Western blot) did not correlate with SERINC internalization function in our assays (S3 Fig), but Nef stability varies substantially among isolates and might contribute in some cases. Furthermore, HIV Env can modulate viral sensitivity to SERINC5 [19] and a recent study found that SERINC5 binds to an “open” conformation of the Env trimer that is induced by the cellular CD4 protein [34], the presence of which can differ on the surface of infected cells in a Nef-dependent manner [55]. However, the relative impact of Env compared to Nef to SERINC antagonism has not been examined carefully and potential functional interactions between nef and env have not yet been studied in detail.

In summary, our results reveal HIV subtype-specific variation in Nef’s ability to counteract SERINC3 and SERINC5 that mirror subtype-specific associations with HIV disease progression in global regions where multiple HIV strains co-circulate. We also identify naturally occurring Nef polymorphisms that are associated with differences in these functions. In particular, polymorphisms at residues 8 and 11 in Nef’s N-terminal anchor domain that selectively impair SERINC3 antagonism activity were found in all HIV subtypes, but are consensus in subtype B, consistent with poor conservation of this function in subtype B clones. Our observations raise the intriguing hypothesis that Nef—and in particular Nef’s SERINC antagonism activity—contributes to subtype-specific differences in HIV pathogenesis. Larger genotype/
phenotype-based analyses should be conducted to assess the impact of Nef on HIV outcomes in diverse global populations.

**Methods**

**Human subjects**

No human subjects were enrolled for this study. Plasma specimens were obtained from antiretroviral naïve chronically HIV-infected individuals, as described previously [30]. Subtype A and subtype D isolates were derived from two Ugandan sites: the Adherence Monitoring Uganda (AMU) cohort from Kampala [56] and the Uganda AIDS Rural Treatment Outcomes (UARTO) cohort from Mbarara [57]. Subtype B isolates were derived from the HAART Observational Medical Evaluation and Research (HOMER) Cohort from British Columbia, Canada [58, 59]. Subtype C isolates were derived from the Sinikithemba cohort from Durban, South Africa [60]. Specimens were selected based on the availability of stored plasma or first-round plasma RNA-derived PCR products spanning the nef region [58].

**Ethics statement**

This study was approved by the Research Ethics Boards at Simon Fraser University and the Providence Health Care/University of British Columbia. Human subject protocols were approved by REBs at the Mbarara University of Science and Technology, University of KwaZulu Natal, or Providence Health Care/University of British Columbia. Participants provided written informed consent or historic specimens were anonymized according to REB-approved procedures for secondary use.

**Cell lines**

CEM-A’02 cells were derived from CEM (a female human acute lymphoblastic leukemia CD4 T cell line) by stably transduction of HLA-A’02:01 using a retroviral vector (murine stem cell virus; Clontech), selected using puromycin, and maintained in RPMI-1640 media supplemented with 10% FBS, 2 mM L-glutamine, 1000 U/mL Penicillin and 1 mg/mL Streptomycin (all from Sigma-Aldrich) at 37˚C with 5% CO2. HEK293T cells (a female human embryonic kidney cell line) and TZM-bl reporter cells (a female human carcinoma cell line, derived from Hela) were cultured in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 1000 U/mL Penicillin and 1 mg/mL Streptomycin.

**Reagents**

The following materials were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 NL4.3 infectious molecular clone (pNL4.3), from Dr. Malcolm Martin [61]; and TZM-bl cells, from Dr. John C. Kappes and Dr. Xiaoyun Wu [62–66]. Rabbit polyclonal anti-Nef antiserum was obtained from the NIBSC Center for AIDS Reagents program (cat. # ARP444, from Dr M Harris). Mouse anti-HA.11 antibody was purchased from Biolegend (clone 16B12) and rabbit polyclonal anti-SERINC3 antiserum was purchased from Abcam (cat # ab65218). pX330-U6-Chimeric_BB-CBh-hSpCas9, used for gene editing of SERINC3, was obtained from Addgene (plasmid #42230, gift from Dr. Feng Zhang) [67, 68].

**Generation of plasmids and expression constructs**

Single phylogenetically representative Nef clones from 360 participants were isolated and characterized previously [30]. Briefly, patient-derived HIV nef alleles were amplified from plasma using nested RT-PCR and cloned into pSELECT-GFPzeo expression plasmid (Invivogen).
this study, Nef clones that displayed poor steady-state detection by Western blot were excluded, resulting in a total of 339 clones (92 subtype A, 91 subtype B, 71 subtype C, and 85 subtype D). These nef sequences are available as Genbank accession numbers KC906733 – KC907077.

A SERINC5 variant encoding an internal HA tag (iHA) was sub-cloned from pBJ5-SERINC5(iHA) [8] into a pSELECT plasmid lacking GFP (p-SELECT-ΔGFP). An analogous SERINC3(iHA) construct was synthesized as a gBlock Gene Fragment (Integrated DNA Technologies; Accession Number NM_006811) with an internal HA tag inserted between amino acids 311 and 312, a Kozak sequence (GCCGCCACC) inserted upstream of the start codon, and unique restriction enzyme cut sites BamHI and SacII located at the 5’ and 3’ ends, respectively, which was subsequently cloned into pSELECT-ΔGFP.

Site-directed mutagenesis

Point mutations in reference Nef strains and primary Nef clones were introduced using overlap PCR extension, as previously described [69].

SERINC, CD4 and HLA class I internalization assays

To assess Nef-mediated internalization of SERINC3 or SERINC5 from the cell surface, 1 × 10^6 CEM-A02 CD4 T cells were co-transfected with 1 μg of pSELECT-GFPzeo encoding nef and 5 μg of pSELECT-SERINC3(iHA)-ΔGFP or pSELECT-SERINC5(iHA)-ΔGFP by electroporation in 150 μl OPTI-mem medium (Thermo Fisher Scientific) using a BioRad GenePulser MXCell instrument (square wave protocol: 250 V, 2000 μF, infinite Ω, 25 millisecond single pulse). Cultures were recovered for 20–22 hours with 350 μl of R10+ medium (RPMI-1640 supplemented with 2 mM L-glutamine, 1000 U/ml Penicillin and 1 mg/ml Streptomycin, all from Sigma-Aldrich) at 37˚C plus 5% CO₂. Following this, 2.5 × 10^5 cells were stained with 0.5 μg of Alexa Fluor 647 anti-HA.11 (BioLegend) and analyzed by flow cytometry for GFP expression (marker for transfected cells) and cell surface SERINC expression (HA tag stain) using a Millipore Guava 8HT instrument. The median fluorescence intensity (MFI) values of SERINC3/5 for each Nef clone were normalized to the positive (pSELECT-nefWT (NL4.3)-GFPzeo) and negative (pSELECT-Δnef) controls using the formula: (MFIΔNef−MFIclone)/(MFIΔNef-MFIWT) × 100, such that Nef function less than or greater than wild type Nef is represented by values of <100% or >100%, respectively. Nef-mediated internalization of CD4 and HLA class I was assessed by flow cytometry using a similar co-transfection protocol, as described previously [30, 33].

Generation of SERINC3 knockout HEK293T cell line

We generated a SERINC3 knockout (KO) derivative of the HEK293T cell line using CRISPR/Cas9 technology. Parental 293T cells were transfected with a pX330-based plasmid encoding previously described target sequences [7] using DNAfectin 2100 (Applied Biological Materials) and then serially diluted into 96-wells to isolate clonal progeny. Disruption of SERINC3 in 293T clones was confirmed by Western blot using rabbit polyclonal anti-SERINC3 (Abcam).

Viral infectivity assays

To assess viral infectivity, 8 × 10^5 SERINC3 KO 293T cells were seeded on 6 well plates and transfected with 2 μg pNL4.3ΔNef, 30 ng pSELECT-SERINC3(iHA)-ΔGFP or pSELECT-SERINC5(iHA)-ΔGFP and 10 ng pSELECT-nef-GFP using DNAfectin 2100 (Applied Biological Materials). Culture supernatants containing viruses were harvested at 48-hours post-
transfection, centrifuged for 10 minutes at 1000 x g to pellet residual cells or debris and then stored as aliquots at -80˚C until use. Viral quantification was done using p24 ELISA (Xpress-Bio). A standardized amount of each virus (5 pg or 10 pg p24) was used to infect 1 x 10^4 TZM-bl reporter cells in a 96-well flat bottom plate in triplicate. Infectivity was measured at 48 hours using Steady-Glo Luciferase (Promega) on a Tecan Infinite M200 PRO plate reader.

**Proximity Ligase Assay (PLA)**

PLA was conducted using Duolink flowPLA Detection Kit—Far Red Mouse/Rabbit kit (Millipore-Sigma). Briefly, 1 x 10^6 CEM A’02 cells were transfected with 1 μg of pSELECT-Nef-GFP and 5 μg pSELECT-SERINC3/5(iHA)-ΔGFP as described above. After 20 hours, cells were treated with BD Cytofix-Cytoperm solution (BD Biosciences), and co-stained with rabbit polyclonal anti-Nef (cat. # ARP444; NIBSC Center for AIDS Reagents) and mouse anti-HA.11 (Biolegend, clone 16B12) overnight at 4˚C. Secondary incubation anti-rabbit PLUS and anti-mouse MINUS probes, ligation, amplification and wash steps were completed in solution as directed by the manufacturer. The median fluorescence intensity (MFI) of cells was quantified on a GUAVA 8HT flow cytometer (Millipore) and results were normalized to those of parental NL4.3 Nef (100%) and empty vector (0%).

**Western blot**

Steady-state Nef expression levels were assessed by transfecting 2.5 x 10^6 CEM-A’02 CD4 T cells with 10 μg of pSELECT-nef-GFPpeoz via electroporation as described above. After 24 hours, cells were pelleted, lysed and prepared as described previously [31]. Nef was labeled using a polyclonal rabbit serum (cat. # ARP444; NIBSC Center for AIDS Reagents) (1:2000) followed by staining with HRP Donkey anti-rabbit IgG antibody (BioLegend) (1:5000). To validate CRISPR/Cas9-mediated knockout of SERINC3 in 293T cells, 2 x 10^6 parental or KO cells were pelleted and lysed. Endogenous SERINC3 expression was detected using rabbit polyclonal anti-SERINC3 antibody (Abcam ab65218) (1:1000 dilution) followed by staining with HRP Donkey anti-rabbit IgG antibody (BioLegend). Proteins were detected using Clarity Western ECL substrate (Bio-rad) and visualized on ImageQuant LAS 4000 imager (GE healthcare).

**Statistical analysis**

Nef sequences were aligned to the reference strain HXB2 (GenBank accession number K03055) and insertions with respect to HXB2 were removed using an in-house alignment algorithm based on the Hy Phy platform [70]. Nef polymorphisms associated with differential *in vitro* SERINC3 or SERINC5 internalization function within each subtype were identified using a custom Perl script. For every Nef polymorphism present in 3 or more unique HXB-aligned sequences per subtype (i.e. a frequency of 3.3–4.2%), clones were repeatedly grouped according to the presence versus absence of the observed variant and the nonparametric Mann-Whitney U-test was then used to compare median SERINC downregulation function between groups. Multiple comparisons were addressed using q-values, the p-value analogue of the false discovery rate (FDR). FDR is the expected proportion of false positives among results deemed significant at a given p-value threshold (e.g. at a q ≤ 0.1, we expect 10% of identified associations to be false positives). Analysis of population level HIV diversity at Nef residues 8 and 11 was done using the AnalyzeAlign tool provided on the HIV Sequence Database at the Los Alamos National Laboratory (www.hiv.lanl.gov). For this, the “Web alignment” dataset was selected, which has been curated to contain only a single sequence per participant and to remove low quality sequences.
All other statistical analyses were performed using Prism v.8 (Graphpad). Since functional data were not distributed normally (based on the Kolmogorov-Smirnov test), non-parametric tests were employed. The Mann-Whitney U test was used to compare differences in median Nef function between subtypes. The Spearman rank sum test was used to examine correlations between Nef functions. Results of two-tailed tests were considered significant if the p-value was less than 0.05.

Supporting information

S1 Fig. Assay to measure SERINC3 and SERINC5 internalization functions of HIV Nef. (TIF)

S2 Fig. Associations between SERINC3 and SERINC5 internalization functions among HIV Nef clones. (TIF)

S3 Fig. Associations between SERINC, CD4 and HLA class I internalization functions and protein expression among HIV Nef clones. (TIF)

S1 Table. Nef polymorphisms associated with SERINC5 internalization function (all p < 0.05). (XLSX)

S2 Table. Nef polymorphisms associated with SERINC3 internalization function (all p < 0.05). (XLSX)

S3 Table. Nef polymorphisms associated with both SERINC3 and SERINC5 internalization function (all p < 0.05). (XLSX)

Acknowledgments

We gratefully acknowledge the contribution of study participants and staff.

Author Contributions

Conceptualization: Steven W. Jin, Mark A. Brockman.

Data curation: Steven W. Jin, Francis M. Mwimanzi, Guinevere Q. Lee.

Formal analysis: Steven W. Jin, Francis M. Mwimanzi, Mark A. Brockman.

Funding acquisition: Zabrina L. Brumme, Mark A. Brockman.

Investigation: Steven W. Jin, Francis M. Mwimanzi.

Methodology: Steven W. Jin, Francis M. Mwimanzi, Jaclyn K. Mann, Guinevere Q. Lee.

Project administration: Steven W. Jin, Francis M. Mwimanzi.

Resources: Mwebesa Bosco Bwana, Chanson J. Brumme, Peter W. Hunt, Jeff N. Martin, David R. Bangsberg, Thumbi Ndung’u, Zabrina L. Brumme.

Supervision: Zabrina L. Brumme, Mark A. Brockman.

Visualization: Steven W. Jin, Francis M. Mwimanzi, Mark A. Brockman.
Natural variation in Nef-mediated SERINC antagonism

Writing – original draft: Steven W. Jin, Mark A. Brockman.

References

1. Goujon C, Moncorge O, Bauby H, Doyle T, Ward CC, Schaller T, et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature. 2013; 502(7472):559–62. https://doi.org/10.1038/nature12542 PMID: 2408477
2. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011; 474(7353):654–7. https://doi.org/10.1038/nature10117 PMID: 21613998
3. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 2008; 451(7177):425–30. https://doi.org/10.1038/nature06553 PMID: 18200009
4. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002; 418(6898):646–50. https://doi.org/10.1038/12542 PMID: 24048477
5. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature. 2004; 427(6977):848–53. https://doi.org/10.1038/nature02343 PMID: 14985764
6. Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell host & microbe. 2010; 8(1):55–67.
7. Rosa A, Chande A, Ziglio S, De Sanctis V, Bertorelli R, Goh SL, et al. HIV-1 Nef promotes infection by excluding SERINC from virion incorporation. Nature. 2015; 526(7572):212–7. https://doi.org/10.1038/nature15400 PMID: 26416733
8. Usami Y, Wu Y, Gottlinger HG. SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. Nature. 2015; 526(7572):218–23. https://doi.org/10.1038/nature15399 PMID: 26416734
9. Firrito C, Bertelli C, Vanzo T, Chande A, Pizzato M. SERINC5 as a New Restriction Factor for Human Immunodeficiency Virus and Murine Leukemia Virus. Annu Rev Virol. 2018; 5(1):323–40. https://doi.org/10.1146/annurev-virology-092917-043308 PMID: 30265629
10. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science. 1995; 270(5238):988–91. https://doi.org/10.1126/science.270.5238.988 PMID: 7481804
11. Kestler HW 3rd, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell. 1991; 65(4):651–62. https://doi.org/10.1016/0092-8674(91)90097-i PMID: 2032289
12. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med. 1995; 332(4):228–32. https://doi.org/10.1056/NEJM199501263320405 PMID: 7808489
13. Garcia JV, Miller AD. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature. 1991; 350(6318):508–11. https://doi.org/10.1038/350508a0 PMID: 2014052
14. Le Gall S, Erdtmann L, Benichou S, Berlioz-Torrent C, Liu L, Benarous R, et al. Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity. 1998; 8(4):483–95. https://doi.org/10.1016/s1074-7613(00)80553-1 PMID: 9586638
15. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytolytic T lymphocytes. Nature. 1998; 391(6665):397–401. https://doi.org/10.1038/34929 PMID: 9450757
16. Schwartz O, Marechal V, Le Gall S, Lemmonier F, Heard JM. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med. 1996; 2(3):338–42. https://doi.org/10.1038/nm0396-338 PMID: 8612235
17. Sood C, Marin M, Chande A, Pizzato M, Melikyan GB. SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins. J Biol Chem. 2017; 292(14):6014–26. https://doi.org/10.1074/jbc.M117.777114 PMID: 28179429
18. Chen YC, Sood C, Marin M, Aaron J, Gratton E, Salaikia K, et al. Super-Resolution Fluorescence Imaging Reveals That Serine Incorporator Protein 5 Inhibits Human Immunodeficiency Virus Fusion by Disrupting Envelope Glycoprotein Clusters. ACS Nano. 2020.
19. Beitari S, Ding S, Pan Q, Finzi A, Liang C. Effect of HIV-1 Env on SERINC5 Antagonism. J Virol. 2017; 91(4).
20. Pye VE, Rosa A, Bertelli C, Struwe WB, Maslen SL, Corey R, et al. A bipartite structural organization defines the SERINC family of HIV-1 restriction factors. Nat Struct Mol Biol. 2020; 27(1):78–83. https://doi.org/10.1038/s41594-019-0357-0 PMID: 31907454

PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008813 September 14, 2020 19 / 22
21. Hemelaar J, Elangovan R, Yun J, Dickson-Tetteh L, Fleminger I, Kirtley S, et al. Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis. The Lancet infectious diseases. 2019; 19(2):143–55. https://doi.org/10.1016/S1473-3099(18)30647-9 PMID: 30509777

22. Kuritzkes DR. HIV-1 subtype as a determinant of disease progression. J Infect Dis. 2008; 197(5):638–9. https://doi.org/10.1086/527417 PMID: 18266606

23. Kanki PJ, Hamel DJ, Sankale JL, Hsieh C, Thor I, Barin F, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis. 1999; 179(1):68–73. https://doi.org/10.1086/314557 PMID: 9841824

24. Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis. 2007; 195(8):1177–80. https://doi.org/10.1086/512682 PMID: 17357054

25. Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F, et al. Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis. 2008; 197(5):707–13. https://doi.org/10.1086/527416 PMID: 18266607

26. McPhee E, Grabowski MK, Gray RH, Ndyanabo A, Ssekasanzu J, Kigozi G, et al. Short Communication: The Interaction of HIV Set Point Viral Load and Subtype on Disease Progression. AIDS Res Hum Retroviruses. 2019; 35(1):49–51. https://doi.org/10.1089/AID.2018.0165 PMID: 30520309

27. Heigele A, Kmiec D, Regensburger K, Langer S, Peiffer L, Sturzel CM, et al. The Potency of Nef-Mediated SERINC5 Antagonism Correlates with the Prevalence of Primate Lentiviruses in the Wild. Cell host & microbe. 2016; 20(3):381–91.

28. Cotton LA, Kuang XT, Le AQ, Carlson JM, Chan B, Chopera DR, et al. Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic. PLoS genetics. 2014; 10(4):e1004295. https://doi.org/10.1371/journal.pgen.1004295 PMID: 24762668

29. Kuang XT, Li X, Anmole G, Mwimanzi P, Shahid A, Le AQ, et al. Impaired Nef function is associated with early control of HIV-1 viremia. J Virol. 2014; 88(17):10200–13. https://doi.org/10.1128/JVI.01334-14 PMID: 24965469

30. Mann JK, Byakwaga H, Kuang XT, Le AQ, Carlson JM, Martin E, et al. Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes. Retrovirology. 2013; 10:1. https://doi.org/10.1186/1742-4690-10-1 PMID: 23289738

31. Mwimanzi P, Markle TJ, Ogata Y, Martin E, Tokunaga M, et al. Attenuation of multiple Nef functions in HIV-1 elite controllers. Retrovirology. 2013; 10:100. https://doi.org/10.1186/1742-4690-10-100 PMID: 24041011

32. Mwimanzi P, Markle TJ, Ogata Y, Martin E, Tokunaga M, Mahiti M, et al. Dynamic range of Nef functions in chronic HIV-1 infection. Virology. 2013; 439(2):74–80. https://doi.org/10.1016/j.virol.2013.02.005 PMID: 23490051

33. Jin SW, Alsahafi N, Kuang XT, Swann SA, Toyoda M, Gottlinger H, et al. Natural HIV-1 Nef Polymorphisms Impair SERINC5 Downregulation Activity. Cell Rep. 2019; 29(6):1449–57 e5. https://doi.org/10.1016/j.celrep.2019.10.007 PMID: 31693887

34. Zhang X, Zhou T, Yang J, Lin Y, Shi J, Zhang X, et al. Identification of SERINC5-001 as the Predominant Spliced Isoform for HIV-1 Restriction. J Virol. 2017; 91(10).

35. Martinez-Bonet M, Palladino C, Briz V, Rudolph JM, Fackler OT, Relloso M, et al. A Conserved GPG-Motif in the HIV-1 Nef Core Is Required for Principal Nef-Activities. PLoS One. 2015; 10(12):e0145239. https://doi.org/10.1371/journal.pone.0145239 PMID: 26700863

36. Evans JP, Liu SL. Multifaceted Roles of TIM-Family Proteins in Virus-Host Interactions. Trends in microbiology. 2019.

37. Geyer M, Peterlin BM. Domain assembly, surface accessibility and sequence conservation in full length HIV-1 Nef. FEBS Lett. 2001; 496(2–3):91–5. https://doi.org/10.1016/S0014-5793(01)02394-8 PMID: 11356189

38. Roeth JF, Collins KL. Human immunodeficiency virus type 1 Nef: adapting to intracellular trafficking pathways. Microbiol Mol Biol Rev. 2006; 70(2):548–63. https://doi.org/10.1128/MMBR.00042-05 PMID: 16760313

39. Soderberg O, Guilberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods. 2006; 3(12):995–1000. https://doi.org/10.1038/nmeth947 PMID: 17072308

40. Carlson JM, Brumme CJ, Martin E, Listgarten J, Brockman MA, Le AQ, et al. Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol. 2012; 86(24):13202–16. https://doi.org/10.1128/JVI.01998-12 PMID: 23055555
41. Kinloch NN, Lee GQ, Carlson JM, Jin SW, Brumme CJ, Byakwaga H, et al. Genotypic and Mechanistic Characterization of Subtype-Specific HIV Adaptation to Host Cellular Immunity. J Virol. 2019; 93(1).

42. Ferdinandy B, Mones E, Vicsek T, Muller V. HIV competition dynamics over sexual networks: first comer advantage conserves founder effects. PLoS computational biology. 2015; 11(2):e1004093. https://doi.org/10.1371/journal.pcbi.1004093 PMID: 25654450

43. Faria NR, Rambaut A, Suchard MA, Baesl G, Bedford T, Ward MJ, et al. HIV epidemiology. The early spread and epidemic ignition of HIV-1 in human populations. Science. 2014; 346(6205):56–61. https://doi.org/10.1126/science.1256739 PMID: 25278604

44. Faria NR, Vidal N, Lourenco J, Raghavani J, Sigaloff KCE, Tatem AJ, et al. Distinct rates and patterns of spread of the major HIV-1 subtypes in Central and East Africa. PLoS Pathog. 2019; 15(12):e1007976. https://doi.org/10.1371/journal.ppat.1007976 PMID: 31809523

45. Ananth S, Morath K, Trautz B, Tibroni N, Shytaj IL, Obermaier B, et al. Multi-functional roles of the N-terminal region of HIV-1SF2 Nef are mediated by three independent protein interaction sites. J Virol. 2019.

46. Gilbert MT, Rambaut A, Wlasiuk G, Spira TJ, Pitchenik AE, Worobey M. The emergence of HIV/AIDS in the Americas and beyond. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(47):18566–70. https://doi.org/10.1073/pnas.0705329104 PMID: 17978186

47. Pepin J. The origins of AIDS: from patient zero to ground zero. J Epidemiol Commun H. 2013; 67(6):473–5.

48. Syna Gift SM, David Chang, Lindsay Wieczorek, Vishakha Sharma, Matthew Creegan, Andrey Tokarev, Nicole Doria-Rose 3, Shelly Krebs, Brittani Barrows, James Schoen, Michael Eller 1, Diane Bolton, John Mascola, Merlin Robb, Nelson Michael, Victoria Polonis. SERINC Expression Varies Significantly Within CD4 T Cells and Monocytes Among Healthy Adults. AIDS Research and Human Retroviruses. 2018; 34(S1).

49. Li M, Waheed AA, Yu J, Zeng C, Chen HY, Zheng YM, et al. TIM-mediated inhibition of HIV-1 release is antagonized by Nef but potentiated by SERINC proteins. Proceedings of the National Academy of Sciences of the United States of America. 2019; 116(12):5705–14. https://doi.org/10.1073/pnas.1819475116 PMID: 30842281

50. Wu Y, Olety B, Weiss ER, Popova E, Yamanaka H, Gottlinger H. Potent Enhancement of HIV-1 Replication in the Absence of SERINC3 and SERINC5. MBio. 2019; 10(3).

51. Trautz B, Pierini V, Wombacher R, Stolp B, Chase AJ, Pizzato M, et al. The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor. J Virol. 2016; 90(23):10915–27. https://doi.org/10.1128/JVI.01246-16 PMID: 27681140

52. Schulte B, Selyutina A, Opp S, Herschhorn A, Sodroski JG, Pizzato M, et al. Localization to detergent-resistant membranes and HIV-1 core entry inhibition correlate with HIV-1 restriction by SERINC5. Virology. 2018; 515:52–65. https://doi.org/10.1016/j.virol.2017.12.005 PMID: 29268082

53. Zhang X, Shi J, Qiu X, Chai Q, Frabutt DA, Schwartz RC, et al. CD4 expression and Env conformation are critical for HIV-1 restriction by SERINC5. J Virol. 2019.

54. Alsahafi N, Ding S, Richard J, Markle T, Brassard N, Walker B, et al. Nef Proteins from HIV-1 Elite Controllers Are Inefficient at Preventing Antibody-Dependent Cellular Cytotoxicity. J Virol. 2015; 90(6):2993–3002. https://doi.org/10.1128/JVI.02973-15 PMID: 26719277

55. Hunt PW, Cao HL, Muzoora C, Ssewanyana I, Bennett J, Emenyonu N, et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS. 2011; 25(17):2123–31. https://doi.org/10.1097/QAD.0b013e32834c4ac1 PMID: 21881481

56. Brumme ZL, Brumme CJ, Heckerman D, Korber BT, Daniels M, Carlson J, et al. Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog. 2007; 3(7):e94. https://doi.org/10.1371/journal.ppat.0030094 PMID: 17616974

57. Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, Brockman MA, et al. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One. 2009; 4(8):e6687. https://doi.org/10.1371/journal.pone.0006687 PMID: 19690814
60. Wright JK, Brumme ZL, Carlson JM, Heckerman D, Kadie CM, Brumme CJ, et al. Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters. J Virol. 2010; 84(20):10820–31. https://doi.org/10.1128/JVI.01084-10 PMID: 20702636

61. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986; 59(2):284–91. https://doi.org/10.1128/JVI.59.2.284-291.1986 PMID: 3016296

62. Platt EJ, Bliska M, Kozak SL, Kabat D, Montefiori DC. Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol. 2009; 83(16):8289–92. https://doi.org/10.1128/JVI.00709-09 PMID: 19474095

63. Takeuchi Y, McClure MO, Pizzato M. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol. 2008; 82(24):12585–8. https://doi.org/10.1128/jvi.00709-09 PMID: 19474095

64. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. agents and chemotherapy. 2002; 46(6):1896–905. https://doi.org/10.1128/aac.46.6.1896-1905.2002 PMID: 12019106

65. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O’Brien WA, Ratner L, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol. 2000; 74(18):8358–67. https://doi.org/10.1128/jvi.74.18.8358-8367.2000 PMID: 10954535

66. Platt EJ, Wehly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol. 1998; 72(4):2855–64. https://doi.org/10.1128/JVI.72.4.2855-2864.1998 PMID: 9526505

67. Ran FA, Heu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013; 8(11):2281–308. https://doi.org/10.1038/nprot.2013.143 PMID: 24157548

68. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013; 339(6121):819–23. https://doi.org/10.1126/science.1231143 PMID: 23287718

69. Jin SW, Markle TJ, Anmole G, Rahimi A, Kuang XT, Brumme ZL, et al. Modulation of TCR-dependent NFAT signaling is impaired in HIV-1 Nef isolates from elite controllers. Virology. 2019; 530:39–50. https://doi.org/10.1016/j.virol.2019.02.008 PMID: 30780124

70. Pond SL, Frost SD, Muse SV. HyPhy: hypothesis testing using phylogenies. Bioinformatics. 2005; 21(5):676–8. https://doi.org/10.1093/bioinformatics/bti079 PMID: 15508596